Bristol-Myers Squibb to Acquire Celgene for About $74 Billion
Bristol-Myers Squibb Co. BMY +1.45% agreed to buy rival CelgeneCorp. CELG +0.18% in a deal valued at about $74 billion, combining two leading sellers of cancer drugs and potentially signaling the return of dealmaking to the pharmaceutical industry. Overall, the merged company will […]
Bristol-Myers Squibb to Acquire Celgene for About $74 Billion Read More »
Translate





